Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12672
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPrice, Timothy Jen
dc.contributor.authorBruhn, M Aen
dc.contributor.authorLee, C Ken
dc.contributor.authorHardingham, J Een
dc.contributor.authorTownsend, A Ren
dc.contributor.authorMann, K Pen
dc.contributor.authorSimes, Jen
dc.contributor.authorWeickhardt, Aen
dc.contributor.authorWrin, J Wen
dc.contributor.authorWilson, Ken
dc.contributor.authorGebski, Ven
dc.contributor.authorVan Hazel, Gen
dc.contributor.authorRobinson, Ben
dc.contributor.authorCunningham, Den
dc.contributor.authorTebbutt, Niall Cen
dc.date.accessioned2015-05-16T02:23:59Z
dc.date.available2015-05-16T02:23:59Z
dc.date.issued2015-03-17en
dc.identifier.citationBritish Journal of Cancer 2015; 112(6): 963-70en
dc.identifier.govdoc25742472en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/12672en
dc.description.abstractMutations affecting RAS genes are now established predictive markers of nonresponse to anti-EGFR antibodies in advanced CRC. This analysis assessed the prognostic and predictive impact of extended RAS and PIK3CA gene mutation status in patients receiving capecitabine plus or minus bevacizumab (±mitomycin C) in the randomised phase III MAX study.DNA was extracted from archival macrodissected formalin-fixed paraffin-embedded tumour tissue. Mutation status was determined using pyrosequencing, confirmed with Sanger sequencing (for equivocal RAS) and correlated with efficacy outcomes. Predictive analyses were undertaken using a test for interaction involving both C vs CB+CBM.Of the available 280 of the 471 (59.4%) patients, mutations in KRAS exons 2, 3 and 4 and NRAS 2, 3 and 4 were as follows: 32%, 2.9%, 2.2%, 1.4%, 0.7% and 0% (total RAS MT 39%). The PIK3CA MT rate was 7.5% exon 9 and 3.6% exon 20. Extended RAS gene mutation status (WT vs MT) had no prognostic impact for PFS (HR 0.91 (0.71-1.17)) or OS (HR 0.95 (0.71-1.25)). The RAS gene mutation status was not predictive of the effectiveness of bevacizumab for PFS (HR 0.56 (0.37-0.85) for RAS MT and HR 0.69 (0.5-0.97) for RAS WT; P for interaction 0.50). The PIK3CA mutation was neither predictive for bevacizumab effect nor prognostic.Of KRAS exon 2 WT patients, 10% had additional RAS mutations. Neither all RAS gene mutation status nor PIK3CA mutation status was prognostic for PFS or OS, or predictive of bevacizumab outcome in patients with advanced CRC.en
dc.language.isoenen
dc.titleCorrelation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer.en
dc.typeJournal Articleen
dc.identifier.journaltitleBritish Journal of Canceren
dc.identifier.affiliationSchool of Medical Sciences, University of Adelaide, Adelaide, SA 5005, Australiaen
dc.identifier.affiliationRoyal Marsden Hospital, London, UKen
dc.identifier.affiliationSir Charles Gardiner Hospital, Perth, WA, Australiaen
dc.identifier.affiliationHaematology-Oncology Department, The Queen Elizabeth Hospital, Woodville, SA 5011, Australiaen
dc.identifier.affiliationNHMRC Clinical Trials Centre, The University of Sydney, Camperdown, NSW 2050, Australiaen
dc.identifier.affiliationAustin Health, Heidelberg, VIC 3084, Australiaen
dc.identifier.affiliationHaematology-Oncology Department, The Queen Elizabeth Hospital, Woodville, SA 5011, Australiaen
dc.identifier.affiliationLudwig Institute for Cancer Research, Heidelberg, VIC 3084, Australiaen
dc.identifier.affiliationSchool of Medical Sciences, University of Adelaide, Adelaide, SA 5005, Australiaen
dc.identifier.affiliationSchool of Medicine, University of Adelaide, Adelaide, SA 5005, Australiaen
dc.identifier.affiliationChristchurch Hospital, Christchurch, New Zealand.en
dc.identifier.doi10.1038/bjc.2015.37en
dc.description.pages963-70en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/25742472en
dc.type.austinJournal Articleen
local.name.researcherTebbutt, Niall C
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.languageiso639-1en-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

10
checked on Mar 18, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.